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Abstract
Purpose The purpose of the trial was to quantify and
compare the efficacy of two different sequences of burst
anti-tachycardia pacing (ATP) strategies for the termination
of fast ventricular tachycardia.
Methods The trial was prospective, multicenter, parallel
and randomized, enrolling patients with an indication for
implantable cardioverter-defibrillator implantation.
Results From February 2004, 925 patients were randomized
and followed-up for 12 months. Eight pulses ATP terminated
64% of episodes vs. 70% in the 15-pulse group (p=0.504).
Fifteen pulses proved significantly better in patients without
a previous history of heart failure (p=0.014) and in patients
with LVEF≥40% (p=0.016). No significant differences
between groups were observed with regard to syncope/
near-syncope occurrence.
Conclusion In the general population, 15-pulse ATP is as
effective and safe as eight-pulse ATP. The efficacy of ATP
on fast ventricular arrhythmias confirmed once more the
striking importance of careful device programming in order
to reduce painful shocks.
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Implantable cardiac defibrillators (ICD) have been proven
to be highly effective in reducing mortality in patients at
risk of sudden cardiac arrest [1, 2]. However, this benefit
entails some morbidities, mainly associated with the pain of
shocks, both appropriate and inappropriate. Up to 25% of
patients receiving multiple shocks report some anxiety or
depression, and find it difficult to get used to living with an
ICD [3–5].
The first review on the pathogenesis of arrhythmia
formation, methods of electrical pacing, response of specific
tachyarrhythmias to pacing and the clinical application of
pacing to terminate and suppress tachyarrhythmias, date
back to 1975. Zipes recognized the high potential of
electrical pacing, especially in view of a technological
development [6].
Later on, other studies compared shock therapy for
ventricular tachycardia with pacing therapy and tried to
evaluate different pacing strategies in terms of efficacy and
safety [7, 8]. Many of the recent studies that have
demonstrated painless effective and safe anti-tachycardia
pacing (ATP) for fast ventricular tachycardias (FVTs), have
used eight pulses at 88% coupling interval ATP as standard
ICD programming to reduce the shocks and morbidity of
ICD therapy [9–11].
ATP is highly effective for FVTs and allows pain-free
treatment. However, some challenging questions remain.
Regarding optimal ATP programming, the optimal number
of beats to use in overdrive pacing to terminate a
ventricular tachycardia has not yet been prospectively
investigated in spontaneous FVTs. Furthermore, there may
be significant differences in the efficacy of ATP sequences
between primary and secondary prevention patients or in
specific subgroups. In order to address these questions, a
randomized, prospective study, called the ADVANCE-D
(Atp DeliVery for PAiNless ICD ThErapy) trial, was
developed in Europe.
2 Methods
ADVANCE-D was a prospective, multicenter, randomized,
controlled, parallel, single-blind trial designed to compare
the efficacy of two different ATP sequences (eight vs. 15
pulses) for the treatment of FVT (320–240 ms) in patients
with Class I or IIA indication for ICD implantation. Details
of the design have been previously reported [12].
In brief, following institutional review board acceptance
of the protocol and registration of informed consent, a total
of 925 patients with standard ICD indications were enrolled
from February 2004 to April 2006 in 60 European centers.
After randomization 1:1 to either eight or 15 ATP pulses at
88% of the tachycardia cycle length (stratified by center),
patients were followed-up for 12 months.
Patients older than 18 years with standard ICD indica-
tions and implanted with a device with ATP delivery
capabilities were included in the study; only ICD patients
believed unlikely to have a substrate for stable monomorphic
ventricular tachycardia (VT) susceptible toATP(hypertrophic
cardiomyopathy, long-QT syndrome, or Brugada syndrome)
were excluded.
Device programming was standardized except for the
initial randomized therapy for FVT (Fig. 1). Detection in
the ventricular fibrillation (VF) zone required that 18 of the
last 24 R–R intervals should have a cycle length (CL)
<320 ms (>188 bpm). Only ICDs capable of programming
a FVT detection zone defined within the VF zone (FVT via
VF) for a CL of 240 to 320 ms (250 to 188 bpm) and ATP
therapy available in this zone were used (Marquis VR mod.
7230, Marquis DR mod. 7274, Maximo VR mod. 7232,
Maximo DR mod. 7278 Entrust DR mod.D153DRG,
Entrust VR mod. D153VRG; all Medtronic Inc).
For the ICD model EnTrust, DR/VR programming of the
ATP during charging feature had to be switched off until
the end of the study.
Following enrolment, patients were randomized according
to a web-based randomization scheme, and ICDs were
programmed consequently. Follow-up examinations were
performed at 3, 6, and 12 months, at which times clinical
status and device performance were assessed. Whenever the
patients hadsymptomatic episodes, anunscheduledfollow-up
examination was performed as soon as possible, preferably
within three working days.
Thestoredelectrogramwasusedtoclassifyallspontaneous
episodes. All arrhythmic events were adjudicated by an
independent, blinded Episode Review Board (ERB). Each
episode was reviewed by two different experts; in the case of
disagreement, the episode was reviewed by the four ERB
members in a plenary session.
Mortality and adverse events were also recorded. All
adverseevents,mortalityandsafetyendpointswereadjudicated
by an independent, blinded Adverse Event Committee.
The primary endpoint was to quantify and compare the
efficacy of two different sequences of Burst ATP strategies
for the termination of ventricular tachycardia (with CL of
240 ms-320 ms) from the baseline to 12 months post-
randomization in patients treated with eight-pulse ATP at
88% versus patients treated with 15-pulse ATP at 88%.
Secondaryendpointspre-specifiedintheprotocolwere:(1)
to estimate ATP efficacy in terminating FVT episodes in
patients treated for primary and secondary prevention; (2) to
estimate the rates of FVT acceleration and degeneration into
VF (acceleration was defined as a decrease in FVT cycle
length greater than 10% as recorded by the device); (3) to
compare the likelihood of syncopal events associated with
128 J Interv Card Electrophysiol (2010) 27:127–135FVT (syncope was defined as transient, self-limiting loss of
consciousness, usually leading to a fall); (4) to estimate the
reduction in the number of shocks delivered for the treatment
of spontaneous FVT; (5) to evaluate predictors of ATP
success. All the secondary endpoints and sub analysis were
pre-specified by protocol.
New York Heart Association (NYHA) class information
was collected at the baseline only for patients with a history
of heart failure.
2.1 Statistical analysis
Sample size calculation and its amendment are described in
the ADVANCE-D design publication [12].
Continuous data were expressed as mean ± standard
deviation, whereas categorical values were expressed as
absolute and relative frequencies. Data were analyzed on an
intention-to-treat basis. To adjust for multiple episodes per
patient, the generalized estimating equations (GEE) method
was used in quantification and comparison of therapy
delivery, syncope, acceleration, and in episode duration
unless otherwise noted [13].
MortalityratewasdeterminedbyKaplan–Meierestimation
and curves were compared by mean of the Log-rank test.
A population-averaged logistic regression, both univariate
and multivariable, was applied in order to study predictors of
efficacy. The multivariable model included all covariates with
a significance below 0.1 on univariate analysis.
Summary statistics for episode measures such as CL were
adjusted for multiple episodes per patient by calculating the
median for each patient and then calculating summary
statistics on the basis of each patient’sm e d i a n .
Statistical analyses were performed by mean of SPSS
12.0 (SPSS Inc., Chicago, Illinois) and Stata SE9.0
(StataCorp, Texas, USA).
3 Results
Enrolment began in February 2004 and follow-up was
completed by April 2007. We randomized 925 patients, 475
to the eight-pulse group and 450 to the 15-pulse group.
Patients with a history of previous myocardial infarction,
significant coronary lesions, or previous myocardial revascu-
larization were considered to have coronary artery disease;
these represented 74.7% of the patients (691 patients). Five
hundred and forty-four patients (58.8%) underwent implanta-
tion for secondary prevention. Mean ejection fraction was
33.9±12.1%. Baseline characteristics are reported in Table 1.
No patient switched from one assigned ATP burst therapy to
the other, or turned off ATP during the study owing to their
physician’s decision (except in one patient during a
hospitalization event). Mean follow-up was 12±3 months.
3.1 Detection of spontaneous episodes
We collected 2,781 tachyarrhythmia episodes with complete
electrogram data in 333 patients. Of these, 2,385 were
classified as spontaneous episodes by the ERB: 1,646 in 243
patients were true VT/VF, whereas 739 episodes in 145
patients were true supraventricular tachyarrhythmia (SVT).
For the true VT/VF episodes, 129 (8%) in 38 patients were
classified as VF, 467 (28%) in 110 patients were classified as
FVT and 1050 (64%) in 160 patients were true VTs. Of the
467 FVT, eight episodes did not receive any ATP treatment
(therapies were programmed off during a hospitalization
event) and were excluded from the analysis (Fig. 2).
3.2 Primary endpoint on therapy efficacy
There was no difference in median FVT CL between eight- and
15-pulse ATP (291 ms for eight pulses versus 290 ms for 15
pulses; p=0.650).
The overall ATP efficacy in terminating FVTepisodes was
71% when unadjusted and 67% when adjusted (95%CI
60–74%). After adjustment, 64% of episodes were terminated
by eight-pulse ATP (95%CI 55–75%) versus 70% (95%CI
60–80%) in the 15-pulse group (p=0.504).
3.3 Secondary endpoints
& Predictors of ATP success in general population:
Univariate and multivariable analyses were performed
on baseline clinical variables in order to determine their
Fig. 1 Detection intervals and
therapy programming description
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population. The independent significant predictors of ATP
success identified were: NYHA functional class deterioration
in HF patients (OR 0.52, 95% CI 0.29–0.95; p=0.033) and
the administration of ACE inhibitors (OR 3.33, 95% CI
1.51–7.36; p=0.003). No other variables were predictive of
ATP success.
The same analysis was performed dividing the population
by randomization groups. Fifteen-pulse burst ATP was
significantly better in patients without a previous history of
heart failure (OR 5.21, 95%CI 1.39–19.50, p=0.014) and in
patients with left ventricular ejection fraction (LVEF)≥40%
(OR 5.97, 95%CI 1.39–25.62, p=0.016).
Eight-pulse ATP was more effective in patients with
previouslyreportedheart failure, but only in those withNYHA
functional class I–II (OR 0.38, 95%CI 0.16–0.91, p=0.029).
& ATP efficacy in primary and secondary prevention
FVT median cycle length was significantly longer in
secondary prevention than in primary prevention patients
(293 ms vs. 285 ms; p=0.041).
As reported above, 58.8% of the patients were implanted
for secondary prevention (57.3% in the eight-pulse group and
60.4% in the 15-pulse group). The adjusted efficacy (GEE)
ofATPforprimarypreventionwas 71.4% intheeight-pulse
group and 69.1% in the 15-pulse group (p=0.798); with
All pts n=925 Group 8 n=475 Group 15 n=450 p value
Male gender, n (%) 811 (87.7%) 409 (86.1%) 402 (89.3%) 0.135
Age, average (standard deviation) 63.7 (11.6) 64.0 (10.9) 63.4 (12.2) 0.412
Secondary prevention 544 (58.8%) 272 (57.3%) 272 (60.4%) 0.326
CAD, n (%) 691 (74.7%) 364 (76.6%) 327 (72.7%) 0.166
HF, n (%) 542 (58.6%) 278 (58.6%) 264 (58.9%) 0.932
Ejection fraction (%), average (SD) 33.9 (12.1) 33.7 (11.8) 34.2 (12.4) 0.532
b
NYHA class, n (%) 0.676
I 49 (9.4%) 30 (11.2%) 19 (7.6%)
II 309 (59.4%) 154 (57.2%) 155 (61.3%)
III 158 (30.4%) 83 (30.9%) 75 (29.9%)
IV 4 (0.8%) 2 (0.7%) 2 (0.8%)
LBBB, n (%) 163 (17.6%) 92 (19.5%) 71 (15.8%) 0.144
ACE inhibitors, n (%)
a 667 (74.9%) 357 (78.5%) 310 (71.3%) 0.013
Amiodarone, n (%)
a 238 (26.7%) 123 (27.0%) 115 (26.4%) 0.841
ARB II, n (%)
a 66 (7.4%) 29 (6.4%) 37 (8.5%) 0.225
Beta-blockers, n (%)
a 558 (62.7%) 276 (60.7%) 282 (64.8%) 0.199
Digitalis, n (%)
a 95 (10.7%) 56 (12.3%) 39 (9.0%) 0.107
Diuretics, n (%)
a 532 (59.8%) 277 (60.9%) 255 (58.6%) 0.492
Other AAD, n (%)
a 17 (1.9%) 4 (0.9%) 13 (3.0%) 0.022
Spironolactone, n (%)
a 279 (31.3%) 152 (33.4%) 127 (29.2%) 0.176
Table 1 Clinical characteristics
of the study population
AAD anti arrhythmic drug, CAD
coronary artery disease, HF
heart failure, LBBB left bundle
branch block
aFisher’s exact test
bMann-Whitney non parametric
test for independent groups
Fig. 2 ERB adjudication
of episodes detected by ICD
as spontaneous ventricular
tachyarrhythmia. Details on
the treatments delivered for
episodes appropriately and
inappropriately detected in the
FVT window are reported.
Not treated episodes that did
not received any treatment.
ATP only episodes treated
only by ATP. Shock episodes
treated with at least one shock
130 J Interv Card Electrophysiol (2010) 27:127–135regard to secondary prevention, the figures were 62.7%
and 69.9% in the eight- and 15-pulse groups, respectively
(p=0.457). No significant differences were found either by
group or by indication (p=0.511 for the eight-pulse group
and p=0.900 for the 15-pulse group).
Univariate analyses were performed on baseline
variables in order to determine their potential correlation
with ATP success in primary and then in secondary
prevention group.
In all the primary prevention patients, the 15-pulse and
eight-pulse ATP burst had similar effectiveness.
In the secondary prevention group 15 pulses were
significantly more effective in patients without a
previous history of heart failure (OR 9.60, 95%CI
1.65–55.87, p=0.012) and in patients with LVEF≥40%
(OR 5.05, 95%CI 1.17–21.73, p=0.030). The same
advantage of the 15-pulse burst was observed in patients
without a previous history of NSVTs (OR 2.61 95%CI
1.07–6.37, p=0.035).
& Acceleration rate
FVT acceleration was observed only for 18 episodes
(3.9%) in 13 patients: 3.9% in the eight-pulse group vs. 4%
in the 15-pulse group (p=0.993) as summarized in Table 2.
Of these 18 episodes, 16 were terminated by shock, while
two spontaneously terminated during battery charging.
None of the accelerated episodes correlated with syncope
or near-syncope.
& Syncope occurrence rate
As summarized in Table 2, seven episodes of syncope
(1.7%) and nine of near-syncope (1.8%) occurred in 14
patients; these were associated to a FVT episode. Syncope
and near-syncope occurred in 0.5% and 2.8% of FVT
episodes, respectively in the eight-pulse group and in 3.2%
and a 0.7% in the 15-pulse group. We found no significant
differences between groups with regard to syncope/near-
syncope occurrence (p=0.690).
& Reduction in number of shocks
In the eight-pulse arm, 59 out of 250 FVT episodes
(22%) required one or more shocks (total shocks 72).
In the 15-pulse arm, 45 out of 209 FVT episodes (21%)
required one or more shocks (total shocks 50). No
significant differences were observed between groups
(p=0.907).
Considering only the inappropriately detected episodes
in the FVT zone (raw numbers described in Fig. 2), the
GEE adjusted rate of delivered shocks (number of shocks
divided by the total number of inappropriately detected
episodes) was not significantly different between the two
groups (67.6% in the eight-pulse vs. 62.9% in the 15-pulse
groups, p=0.647).
& Coronary artery disease (CAD) patients vs. non-CAD
patients
Eight- and 15-pulse ATP had the same efficacy in
treating FVT in CAD and non-CAD patients (eight-pulse
efficacy: 63.2% in CAD patients and 69.9% in non-CAD
patients; 15-pulse efficacy: 68.2% in CAD patients and
74.5% in non-CAD). There were no significant differences
either between arms or between CAD and non-CAD
patients (p values always >0.5).
& Mortality
During the study, 57 deaths occurred (6.2%): 31 (6.5%) in
the eight-pulse arm and 26 (5.8%) in the 15-pulse arm. Seven
patients(0.8%)havebeensubjectedtocardiactransplantation,
two deaths were classified as sudden, 21 as non-sudden, ten
non-cardiac and 17 unknown. No significant difference was
found between the two randomization groups in terms of
causes of death (all p values>0.5) or overall mortality
(Log-rank=0.22; p=0.636).
4 Discussion
The medical literature on the adverse psychological
consequences of ICD shocks, whether appropriate or not,
is growing.
The PainfreeRx IandPainfreeRxIIstudies foundpainless
ATP to be safe and effective in treating monomorphic
ventricular arrhythmias, showing a relative shock reduction
of 70–92%, depending mainly on cycle length [14, 15].
Painfree Rx II involved 634 patients in 42 US centers; the
first therapy in the FVT zone was a single ATP sequence of
an eight-pulse burst-pacing train at 88% of the ventricular
tachycardia (VT) cycle length (CL). On comparing ATP and
shock therapy, no statistically significant differences were
found in arrhythmia acceleration, syncope, or mortality.
Additionally, after 12 months, the ATP arm showed a
significant improvement in five of the eight subscales in
the Medical Outcomes Study 36-item short-form General
Health Survey (physical functioning, role physical, bodily
pain, social functioning, and role emotional), as well as in
the two summaries (mental and physical) [15].
Moreover, recently published studies report that both
appropriateandinappropriateshocksaresignificantpredictors
of death. In the SCD-HeFT study, the risk of death among
patients who received more than one appropriate shock was
twice as high as among patients who received a single
appropriate shock; furthermore, shocks were much stronger
predictors of an adverse outcome in ischemic than in
non-ischemic heart failure patients [16]. These results
are similar to those obtained the Multicenter Automatic
Defibrillator Implantation Trial II (MADIT II), which also
J Interv Card Electrophysiol (2010) 27:127–135 131showed that the risk of death increased by a factor of 3 after
an appropriate ICD shock [17]. Thus, over treatment with
shocks has an impact on both the mental and physical status
of the patient, as well as reducing device longevity as a result
of excessive battery drain.
The ADVANCE-D trial results showed that ATP therapy
is highly effective and safe in treating fast ventricular
tachyarrhythmia in general population. The results are
confirmed in all the subgroups analyzed: ischemic, non-
ischemic, primary, and secondary prevention patients.
Concerning ATP success predictors, the administration of
ACE inhibitors seems to improve ATP efficacy and in the
HF population, the efficacy of ATP treatment is greater in
less functionally compromised patients. These results may
have been coincidental observation and will require further
confirmation by means of a specific study.
Owing to the high efficacy of ATP and the consequent
reduction in shocks, it may be claimed that ATP should
always be programmed as a first-option electrical therapy
for fast ventricular tachyarrhythmias.
These European data are in close agreement with those
reported by the Painfree RxII study (which was run in the
USA) with regard to episode distribution, therapy efficacy,
safety, and mortality.
The importance and potential benefits of ICD shock
reduction, by optimizing ATP therapy seem clear. Previous
studies on the electrical treatment of fast ventricular
tachycardia have examined several empirical ATP strate-
gies, such as burst with different numbers of pulses or ramp
with beat-to-beat decremented cycle length [8, 18], without
obtaining clear proof of the best ATP programming. The
ADVANCE-D study compared two different strategies of
burst pacing in the general ICD population and in
subgroups with specific baseline characteristics. The choice
of the two therapies was prompted, on the one hand, by the
Painfree experience of using eight pulses at 88% coupling
interval (safety proved), and, on the other hand, by various
smaller studies in which a different ATP strategy was used.
Peinado et al. [8] tested the safety and efficacy of four
different pacing sequences in 45 patients with spontaneous
or induced monomorphic ventricular tachycardia (MVT).
Each patient randomly received each ATP sequence at
3-month intervals. The different pacing modes were based
on the number of beats (seven vs. 15) and coupling interval
(91 vs. 81%). The success rate was significantly higher for
15 (78%) than for seven beats (68%) at a coupling interval
of 91%, but no differences in termination were found when
coupling intervals of 81% were used. Although the
acceleration rate was higher with 15 pulses, this difference
did not reach statistical significance. They concluded that
the longer, but less aggressive ATP strategy was more
effective and safer.
On the basis of this evidence, we selected 15-pulse ATP at
88% coupling interval, as an alternative to eight-pulse ATP in
the hypothesis that a higher number of pulses would better
penetrate into the arrhythmic circuit. We tried to minimize the
chance of acceleration by using a coupling interval of proven
safety. We proved that 15-pulse ATP is, in the general ICD
population, as effective as the eight-pulse ATP and is equally
safe. The study focused only on faster ventricular tachycardia
episodes and did not allow any analysis of ICD patients with
slower ventricular arrhythmias, in whom prolonged duration
of ATP pulses might be more effective. This last hypothesis
needs further evaluation.
The only significant difference in effectiveness was
observed in the subgroup of patients without heart failure
at the baseline or with an ejection fraction of 40% or higher.
This specific subgroup was not included among the pre-
specified analysis therefore the result reported should be
validated by further randomized studies.
Overall, ADVANCE-D does not show strong evidence
of the superiority of one specific ATP strategy. It does,
Table 2 Safety data comparison
All pts (108pts) 8 pulses (57pts) 15 pulses (51pts) p value
Syncope related to FVT (pts) 5 (4.6%) 1 (1.8%) 4 (7.8%) 0.186
a
Syncope related to FVT (episodes) 7 (1.7%) 1 (0.5%) 6 (3.2%) 0.169
Near-syncope related to FVT (pts) 9 (8.3%) 7 (12.3%) 2 (3.9%) 0.167
a
Near-syncope related to FVT (episodes) 9 (1.8%) 7 (2.8%) 2 (0.7%) 0.046
Syncope/Near-syncope related to FVT (pts) 14 (13.0%) 8 (14.0%) 6 (11.8%) 0.726
Syncope/Near-syncope related to FVT (episodes) 16 (3.6%) 8 (3.2%) 8 (4.1%) 0.690
Acceleration (pts) 13 (11.5%) 7 (11.5%) 6 (11.5%) 0.992
Acceleration (episodes) 18 (3.9%) 10 (3.9%) 8 (4.0%) 0.993
Percentages regarding episodes were corrected by means of GEE analysis
FVT fast ventricular tachycardia
aFisher’s exact test
132 J Interv Card Electrophysiol (2010) 27:127–135however, definitively confirm the marked impact of ATP
therapy on the majority of fast ventricular arrhythmias in
ICD patients.
5 Conclusion
The results of the Painfree trials regarding the importance
of shock reduction have, in recent years, raised a relevant
clinical question as to the best programming of ATP
therapies. Many hypotheses have emerged from the results
of small studies in which different types of burst were
investigated. These hypotheses demanded final clarification
by means of a prospective, parallel, randomized trial.
The ADVANCE-D trial fulfilled these requirements and
demonstrated that 15-pulse ATP in the general population
of ICD-indicated patients is as effective and safe as eight-
pulse ATP. The efficacy of ATP on fast ventricular
arrhythmias confirmed once more the striking importance
of careful device programming, the first goal of which
should be to reduce shocks.
6 Limitations
The study was performed using devices provided by a
single manufacturer (Medtronic Inc.). The definition of
FVT was determined as all the VT episodes with cycle
length of 320–240 ms. The choice of the above-
mentioned window was made arbitrarily although
inspired by previously published international trials
[14, 15]. The final number of FVT episodes represented
only the 28% of the overall number of arrhythmic
episodes in 110 patients.
The pacing algorithm described in our paper was
specifically focused on FVT only, although such scenario
does not represent daily practice in which the devices are
usually programmed using different strategies, with multi-
ple ATP sequences and short-burst pacing, tailored on
clinical needs.
One possible confounding factor in estimating ATP
success is the possibility that ATP may appear to
successfully treat VT that would have otherwise self-
terminated. For the same reason, the shock rate reduction
cannot be estimated based on the number of VT episodes
terminated by ATP.
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